Analysts’ Opinions Are Mixed on These Healthcare Stocks: Perrigo Company (NYSE: PRGO), Danaher Corp (NYSE: DHR) and Selecta Biosciences (NASDAQ: SELB)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Perrigo Company (NYSE: PRGO), Danaher Corp (NYSE: DHR) and Selecta Biosciences (NASDAQ: SELB).

Perrigo Company (NYSE: PRGO)

In a report issued on August 10, Annabel Samimy from Stifel Nicolaus reiterated a Hold rating on Perrigo Company (NYSE: PRGO), with a price target of $80. The company’s shares closed yesterday at $78.49.

According to TipRanks.com, Samimy is a 4-star analyst with an average return of 9.7% and a 47.7% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Corcept Therapeutics Inc, and Supernus Pharmaceuticals.

Currently, the analyst consensus on Perrigo Company is Moderate Buy and the average price target is $78.83, representing a 0.4% upside.

In a report released yesterday, Goldman Sachs also upgraded the stock to Hold.
Danaher Corp (NYSE: DHR)

In a report issued on August 10, Robert McCarthy from Stifel Nicolaus reiterated a Buy rating on Danaher Corp (NYSE: DHR), with a price target of $97. The company’s shares closed yesterday at $79.82.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 11.7% and a 76.0% success rate. McCarthy covers the Industrial Goods sector, focusing on stocks such as Lincoln Electric Holdings, Emerson Electric Company, and United Technologies Corp.

Currently, the analyst consensus on Danaher Corp is Moderate Buy and the average price target is $93.25, representing a 16.8% upside.

In a report issued on August 3, Jefferies also reiterated a Buy rating on the stock with a $95 price target.
Selecta Biosciences (NASDAQ: SELB)

In a report released yesterday, Thomas Shrader from Stifel Nicolaus reiterated a Buy rating on Selecta Biosciences (NASDAQ: SELB), with a price target of $32. The company’s shares closed yesterday at $15.67.

According to TipRanks.com, Shrader is a 5-star analyst with an average return of 20.8% and a 49.6% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Voyager Therapeutics Inc, and Molecular Templates Inc.

Currently, the analyst consensus on Selecta Biosciences is Moderate Buy and the average price target is $28.50, representing an 81.9% upside.

In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $25 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.